Pseudomonas aeruginosa is a widespread opportunistic pathogen that causes bloodstream, urinary tract, burn wounds infections and is one of the largest pathogens that infect cystic fibrosis patients’ airways and can be life-threatening for P. aeruginosa infections. In addition, P. aeruginosa remains one of the most significant and difficult nosocomial pathogens to handle. Increasingly, multi-drug resistance (MDR) strains are identified and the option of therapy is often very limited in these cases, particularly when searching for antimicrobial combinations to treat serious infections. The fact that no new antimicrobial agents are active against the MDR strains of P. aeruginosa is an additional matter of concern. In recent decades, bacterial drug resistance has increased, but the rate of discovery of new antibiotics has decreased steadily. The fight for new, powerful antibacterial agents has therefore become a top priority. This chapter illustrates and explores the current state of several innovative therapeutic methods that can be further discussed in clinical practice in the treatment of P. aeruginosa infections.
Part of the book: Pseudomonas aeruginosa